Ventyx BiosciencesVTYX
Market Cap: $167M
About: Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Employees: 73
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
3% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 37
7% less funds holding
Funds holding: 125 [Q1] → 116 (-9) [Q2]
20.75% less ownership
Funds ownership: 101.53% [Q1] → 80.78% (-20.75%) [Q2]
25% less call options, than puts
Call options by funds: $670K | Put options by funds: $896K
30% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 30
60% less capital invested
Capital invested by funds: $331M [Q1] → $132M (-$199M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Wells Fargo Derek Archila 0% 1-year accuracy 0 / 1 met price target | 364%upside $11 | Overweight Maintained | 12 Aug 2024 |
Canaccord Genuity Edward Nash 75% 1-year accuracy 3 / 4 met price target | 491%upside $14 | Buy Maintained | 12 Aug 2024 |
HC Wainwright & Co. Emily Bodnar 28% 1-year accuracy 16 / 57 met price target | 153%upside $6 | Neutral Reiterated | 30 Jul 2024 |
Financial journalist opinion
Based on 3 articles about VTYX published over the past 30 days